On August 31, 2023, Dr. B.Partha Saradhi Reddy, Chairman of Hetero Labs Limited,Mr. Bheemireddy Murali Krishnar Reddy, President of Emerging Markets,Mr. Variyath Muraleedharan, VP of International Markets,Mr. Suman Reddy Bandi, Head of API,and Tanya Wang, BD of Formulation， together visited Shenzhen Beimei Pharmaceutical Co., Ltd. Ms. Wu Guangmei, C...

Recently, Shenzhen Beimei Pharmaceutical Co., Ltd. (hereinafter referred to as "Beimei Pharma") has completed a newfinancinground with investors including Jiangsu Jinqiao Private Equity Fund Management Co., Ltd., Nanshan SEIInvestment and Jiangsu Aosaikang Pharmaceutical Co., Ltd. This fund raisedwill be used to continue to promote the commercialization of seve...

August 2, 2023, Shenzhen BeimeiPharmaceutical Co., Ltd. (hereinafter referred to as "BeimeiPharmaceuticals") in collaboration with Hetero Labs Limited is pleased to announce that ourimported drug formulation "Lacosamide Oral Solution (Trade Name: 乐美定®)" has successfully received approval from the NMPA, the National Medical Products Administration,for...

On July 27, 2023, Shenzhen Beimei Pharmaceutical Co., LTD. (hereinafter referred to as "Beimei Pharmaceutical") first self-developed product "atomoxetine hydrochloride oral solution (trade name: 贝择思®)” has been successfully approved by the Chinese CDE for the treatment of attention deficit/hyperactivity disorder (ADHD) in children and adolescents aged 6 years...

Recently, the three-day CPHI&PMEC China 2023were held atthe Shanghai New International Expo Center. Hetero Labs Limited, the premiumpartner of Shenzhen Beimei Pharmaceutical Co., Ltd.,participated inthe exhibition and awarded Beimei Pharmaceutical The Most Valuable PartnerCollaboration Award.(BeiMei Pharma's Chairman and CEO, Claire Wu, receives the ...

June 25, 2023, the production base of Beimei Pharma (a wholly-owned subsidiary of Beimei Pharmaceutical—Jiangsu Beimei Pharmaceutical Co., Ltd.) successfully settled in the International Pharmaceutical Innovation Industrial Park of Lianyungang Free Trade Zone. The attendees inthe ceremony were: JiajiongZhang, Deputy Mayor of Lianyungang City,YuanYin, Deputy Director ...

After the applicationof procaterol hydrochloride oral solution was accepted on May 29, 2023, our company had another good news again this week. On June 6, 2023, Shenzhen Beimei Pharmaceutical Co., LTD. (hereinafter referred to as "Beimei Pharmaceutical") has officially received the acceptance letter issued by the Drug Evaluation Center of the National Medical Products ...

On May 29, 2023, Shenzhen Beimei Pharmaceutical Co., LTD. (hereinafter referred to as "Beimei Pharmaceutical") has officially received the acceptance letter issued by the Drug Evaluation Center of the National Medical Products Administration. The procaterol hydrochloride oral solution, which isindependently developed by Beimei Pharmaceutical,its application was accep...

A few days ago, Shenzhen Small and medium-sized Enterprise Service Bureau released the "Shenzhen Small and Medium-sized Enterprise Service Bureau- the list of Shenzhen SRDI small and medium-sized enterprises in 2022", after enterprise declaration, expert review and other aspects, with the outstanding performance of children medicine field, Shenzhen Beimei Pharmaceutic...